Inflammation is receiving increasing attention for a potential role in residual CV risk. Follow recent insights into the importance of inflammation of CVD.
A subanalysis of the CANTOS study showed that modulation of the IL-6 signaling pathway with IL-1β inhibitor canakinumab, associates with reduced CV event rates, independent of lipid lowering.
The testosterone/estradiol ratio reflects both systemic and plaque inflammation in men undergoing carotid endarterectomy. Low ratio was associated with higher MACE risk, especially in overweight men.
Pre-meal yogurt consumption improved acute postprandial dysfunction after a high-fat, high-calorie meal in obese and non-obese women.
The CIRT trial evaluating low-dose methotrexate to lower CV risk has been stopped early, not based on any substantive safety concerns.
A small study found antibodies in plasma and heart muscle of end-stage heart failure patients, and more so if HF was caused by ischemic heart disease than by cardiomyopathy.
Levels of pro-inflammatory biomarkers were significantly elevated in decompensated compared with stable HF patients with preserved ejection fraction, and some were linked with altered diastolic function.
Prof. Paul Ridker discusses the insights that originate from the CANTOS trial, in which reducing inflammation with canakinumab reduced CV events. These findings have implications for the management of residual risk.
In a double-blind pilot study, a single lean vegan-donor fecal microbiota transplantation in obese male patients with metabolic syndrome did not alter markers of arterial wall inflammation.
ACC 2018 A prespecified FOURIER-analysis showed that evolocumab decreases CV events across hsCRP strata, with greater absolute risk reductions in patients with higher baseline hsCRP.
ACC 2018 Due to the observed link between inflammation and aberrant insulin regulation, a key secondary outcomes of the CANTOS trial was new onset T2DM in patients with prediabetes at baseline.
ACC 2018 A new analysis of the CANTOS trial showed that IL-1β inhibition in patients with stage 3 kidney disease did not slow progression to renal failure, but did beneficially alter outcomes in these very high risk patients.
ACC 2018 In a sub-analysis of the CANTOS trial, canakinumab showed a similar CV event reduction in diabetics and non-diabetics, but did not prevent the progression from pre-diabetes to diabetes.